Black Diamond Therapeutics Inc (BDTX)
2.43
0.00 (0.00%)
USD |
NASDAQ |
Nov 21, 16:00
2.42
-0.01
(-0.41%)
Pre-Market: 08:18
Black Diamond Therapeutics Enterprise Value: 24.82M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 24.82M |
| November 20, 2024 | 24.82M |
| November 19, 2024 | 31.61M |
| November 18, 2024 | 28.78M |
| November 15, 2024 | 35.57M |
| November 14, 2024 | 48.59M |
| November 13, 2024 | 64.43M |
| November 12, 2024 | 70.65M |
| November 11, 2024 | 78.58M |
| November 08, 2024 | 73.48M |
| November 07, 2024 | 67.26M |
| November 06, 2024 | 73.48M |
| November 05, 2024 | 71.22M |
| November 04, 2024 | 56.51M |
| November 01, 2024 | 50.85M |
| October 31, 2024 | 42.36M |
| October 30, 2024 | 49.54M |
| October 29, 2024 | 48.97M |
| October 28, 2024 | 52.36M |
| October 25, 2024 | 55.75M |
| October 24, 2024 | 59.14M |
| October 23, 2024 | 60.28M |
| October 22, 2024 | 74.41M |
| October 21, 2024 | 68.75M |
| October 18, 2024 | 74.41M |
| Date | Value |
|---|---|
| October 17, 2024 | 69.32M |
| October 16, 2024 | 79.49M |
| October 15, 2024 | 79.49M |
| October 14, 2024 | 84.01M |
| October 11, 2024 | 75.54M |
| October 10, 2024 | 81.75M |
| October 09, 2024 | 87.97M |
| October 08, 2024 | 88.25M |
| October 07, 2024 | 94.19M |
| October 04, 2024 | 99.28M |
| October 03, 2024 | 94.19M |
| October 02, 2024 | 112.56M |
| October 01, 2024 | 123.01M |
| September 30, 2024 | 133.19M |
| September 27, 2024 | 116.04M |
| September 26, 2024 | 126.22M |
| September 25, 2024 | 114.35M |
| September 24, 2024 | 135.82M |
| September 23, 2024 | 131.30M |
| September 20, 2024 | 145.99M |
| September 19, 2024 | 147.12M |
| September 18, 2024 | 144.30M |
| September 17, 2024 | 149.67M |
| September 16, 2024 | 183.29M |
| September 13, 2024 | 226.79M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-125.30M
Minimum
May 25 2022
1.342B
Maximum
Jul 01 2020
246.04M
Average
85.27M
Median
Sep 23 2021
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals Inc | 74.00B |
| Vanda Pharmaceuticals Inc | -88.22M |
| Ligand Pharmaceuticals Inc | 1.983B |
| Agios Pharmaceuticals Inc | 2.163B |
| ADMA Biologics Inc | 5.050B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.56M |
| Total Expenses (Quarterly) | 18.13M |
| EPS Diluted (Quarterly) | -0.28 |
| Earnings Yield | -54.73% |